We are live on ! Find out more
NIP

Nicholas Investment Partners Portfolio holdings

AUM $1.39B
1-Year Est. Return 97.11%
This Fund
S&P 500
This Quarter Est. Return
+6.34%
1 Year Est. Return
+97.11%
3 Year Est. Return
+361.61%
5 Year Est. Return
+496.81%
10 Year Est. Return
+3,647.69%
AUM
$1.32B
AUM Growth
+$174M
Cap. Flow
+$74.4M
Cap. Flow %
5.65%
Top 10 Hldgs %
23.43%
Holding
224
New
43
Increased
51
Reduced
51
Closed
37

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$31.9M
2
UTHR icon
United Therapeutics
UTHR
+$29.5M
3
VRNA
Verona Pharma
VRNA
+$20.3M
4
ARGX icon
argenx
ARGX
+$19.4M
5
DAWN
Day One Biopharmaceuticals
DAWN
+$16M

Top Sells

Rank Stock Value
1
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$21.9M
2
NARI
Inari Medical, Inc. Common Stock
NARI
+$16.5M
3
RGEN icon
Repligen
RGEN
+$14.8M
4
EXE
Expand Energy Corp
EXE
+$14.3M
5
BILL icon
BILL Holdings
BILL
+$13.8M

Sector Composition

Rank Sector Weight
1 Healthcare 52.51%
2 Technology 11.88%
3 Industrials 9.25%
4 Consumer Discretionary 7.08%
5 Energy 4.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
1
argenx
ARGX
$52B
$44.2M 3.36%
118,625
+52,480
+79% +$19.4M
LNTH icon
2
Lantheus
LNTH
$6.59B
$31.2M 2.37%
378,105
+69,810
+23% +$4.5M
ESTA icon
3
Establishment Labs
ESTA
$2.73B
$30.9M 2.35%
456,484
+89,310
+24% +$6.12M
KRYS icon
4
Krystal Biotech
KRYS
$9.21B
$30M 2.28%
374,718
+107,629
+40% +$8.46M
LEGN icon
5
Legend Biotech
LEGN
$3.68B
$29.7M 2.26%
615,333
+216,218
+54% +$10.6M
RXDX
6
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$29.3M 2.23%
272,910
-10,336
-4% -$1.19M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$119B
$28.4M 2.16%
90,291
+42,050
+87% +$12.6M
MDGL icon
8
Madrigal Pharmaceuticals
MDGL
$11.1B
$28.4M 2.16%
+117,047
New +$31.9M
KRTX
9
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$28.3M 2.15%
155,822
+58,694
+60% +$11.2M
TMDX icon
10
Transmedics
TMDX
$2.82B
$27.8M 2.11%
367,408
+77,704
+27% +$5.37M
INSP icon
11
Inspire Medical Systems
INSP
$1.5B
$27.8M 2.11%
118,858
+37,123
+45% +$9.38M
ASND icon
12
Ascendis Pharma A/S
ASND
$16B
$27M 2.05%
251,387
+85,450
+51% +$9.78M
UTHR icon
13
United Therapeutics
UTHR
$25.7B
$26.8M 2.03%
+119,506
New +$29.5M
SRPT icon
14
Sarepta Therapeutics
SRPT
$1.68B
$25.8M 1.96%
187,481
+97,091
+107% +$12.6M
SWAV
15
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$24.5M 1.86%
112,907
+28,400
+34% +$5.53M
PODD icon
16
Insulet
PODD
$11.8B
$23.6M 1.79%
73,983
+24,958
+51% +$7.4M
KDNY
17
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$22.5M 1.71%
972,191
+329,471
+51% +$7.85M
APLS
18
DELISTED
Apellis Pharmaceuticals
APLS
$22.2M 1.69%
336,951
+88,668
+36% +$5.12M
CYTK icon
19
Cytokinetics
CYTK
$10.4B
$21.5M 1.63%
610,990
+59,862
+11% +$2.44M
DAWN
20
DELISTED
Day One Biopharmaceuticals
DAWN
$21.4M 1.63%
1,603,390
+816,836
+104% +$16M
AXSM icon
21
Axsome Therapeutics
AXSM
$10.9B
$21M 1.6%
340,430
+140,176
+70% +$9.21M
LSCC icon
22
Lattice Semiconductor
LSCC
$18B
$20M 1.52%
209,436
-6,915
-3% -$569K
MPWR icon
23
Monolithic Power Systems
MPWR
$66B
$19.9M 1.52%
39,843
-5,766
-13% -$2.65M
VRNA
24
DELISTED
Verona Pharma
VRNA
$18.9M 1.44%
+941,300
New +$20.3M
TFII icon
25
TFI International
TFII
$11.1B
$18.7M 1.42%
156,493
+1,587
+1% +$185K
1
2 3 4 5

Similar funds

FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
1CP
1607 Capital Partners Richmond, Virginia $1.39B AUM 8.35% 1-Year Est. Return
OCM
Opti Capital Management New York $1.39B AUM 0% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
TA
Trivest Advisors Hong Kong $1.39B AUM 273.03% 1-Year Est. Return
AU
Algebris (UK) London, United Kingdom $1.38B AUM 3.87% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
BCP
Blue Chip Partners Farmington Hills, Michigan $1.39B AUM 22.32% 1-Year Est. Return

Nicholas Investment Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Nicholas Investment Partners held 224 positions worth $1.32B, up 15% from $1.14B the previous quarter. Its ten largest holdings account for 23% of the portfolio.

Nicholas Investment Partners deployed $74.4M of net new capital in Q1 2023, opening 43 new positions and adding to 51 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 117,047 shares worth $28.4M.

By sector, the portfolio is most concentrated in Healthcare at 53% of assets, up from 44% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Expand Energy Corp, an estimated $14.3M trimmed.

  • Nicholas Investment Partners's largest Q1 2023 buy was Madrigal Pharmaceuticals: 117,047 shares worth $28.4M.
  • Nicholas Investment Partners added most to argenx in Q1 2023, an estimated $19.4M increase.
  • Nicholas Investment Partners's biggest Q1 2023 reduction was Expand Energy Corp, cutting an estimated $14.3M.
  • Nicholas Investment Partners fully exited Intra-Cellular Therapies Inc. in Q1 2023, selling an estimated $21.9M.
  • Nicholas Investment Partners's ten largest holdings make up 23% of its $1.32B portfolio in Q1 2023.
  • Nicholas Investment Partners opened 43 new positions and closed 37 in Q1 2023.
  • Nicholas Investment Partners's portfolio value rose 15% quarter-over-quarter to $1.32B.

Based on Nicholas Investment Partners's 13F filing for Q1 2023, filed 12 May 2023.